We have established several companies to facilitate research translation and to promote collaboration. These are some examples of start-up companies which have been created with intellectual property developed at the Institute.

IonOpticks

IonOpticks develops and manufactures an innovative nano capillary chromatography column with integrated emitter tip used in the proteomics research field.

Spun out of the Walter and Eliza Hall Institute, it successfully launched its nano capillary chromatography columns to the global proteomics research market in 2017. Their columns were developed for analytical applications used in medical research such as cancer, Parkinson’s disease and other age-related diseases. The product provides a unique ability to enhance the sensitivity of biological sample analysis, enabling scientists to achieve a 25 per cent improvement in performance compared to other commercially available solutions.

Anaxis Pharma Pty Ltd

Anaxis Pharma Pty Ltd is an Australian Biotech company developing novel inhibitors / modulators of cell death, specifically necroptosis, an inflammatory form of programmed cell death.

As an innovative joint venture between Synthesis Research and the Walter and Eliza Hall Institute of Medical Research, we leverage the extensive expertise and capabilities of the Institute, with the medicinal chemistry experience available to SYNthesis Research.

Genera Biosystems Limited

An Australian publicly listed company (ASX: GBI) that develops and commercialises multiplexed molecular diagnostic tests, based upon its proprietary AmpaSand^TM bead-based technology.

Genera’s first product on sale is PapType^TM, a highly competitive molecular diagnostic test for the simultaneous detection and genotyping of the 14 high-risk types of human papillomavirus (HPV) and RTIplex, a multiplexed test for 15 pathogens of the upper respiratory tract. The company has a number of other products in its development pipeline.

MuriGen Therapeutics Limited

An Australian-based drug discovery and development company building a portfolio of novel drugs for unmet medical needs across a number of therapeutic areas including cancer, arthritis, thrombocytopenia and inflammation.

By leveraging its proprietary drug discovery platform, MuriGen Therapeutics is working towards the validation of novel drug targets that have the potential to provide significant benefits for researchers, health care practitioners, and patients.

Catalyst Therapeutics

Catalyst Therapeutics Pty Ltd, founded in 2012, is a joint venture between the Walter and Eliza Hall Institute of Medical Research and SYNthesis Research Pty Ltd. The company facilitates and accelerates the commercialisation of small molecule drug discoveries originating at the Institute.